Vaccine-induced thrombotic thrombocytopaenia
Meaning of vaccine-induced thrombotic thrombocytopaenia: For the purposes of this Statement of Principles, vaccine-induced thrombotic thrombocytopaenia means a disorder of coagulation in which there is formation of blood clots in the vascular system in association with a low platelet count, in a person with no exposure to heparin within the previous 30 days.
Reasonable Hypothesis (RH) — Statement of Principles No. 33 of 2022
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting vaccine- induced thrombotic thrombocytopaenia or death from vaccine-induced thrombotic thrombocytopaenia with the circumstances of a person's relevant service:
- (1)having received an adenovirus vector coronavirus disease 2019 (COVID-19) vaccine within the 100 days before the clinical onset of vaccine-induced thrombotic thrombocytopaenia; (a) Ad26.COV2.S (Janssen COVID-19 Vaccine); (b) ChAdOx1 nCoV-19 (Vaxevria, Oxford/Astra-Zeneca); (c) Gam-COVID-Vac (Sputnik V, Sputnik Light); and (d) AD5-nCOV (Convidecia);
Note: Examples of adenovirus vector COVID-19 vaccines include:.
- (2)inability to obtain appropriate clinical management for vaccine-induced thrombotic thrombocytopaenia;
Aggravation-only factors: the factors in subsection 8(2) apply only to material contribution to, or aggravation of, the condition where it was suffered or contracted before or during (but did not arise out of) the person’s relevant service.
Balance of Probabilities (BoP) — Statement of Principles No. 34 of 2022
2 factors
At least one of the following factors must exist before it can be said that, on the balance of probabilities, vaccine-induced thrombotic thrombocytopaenia or death from vaccine-induced thrombotic thrombocytopaenia is connected with the circumstances of a person's relevant service:
- (1)having received an adenovirus vector coronavirus disease 2019 (COVID-19) vaccine within the 100 days before the clinical onset of vaccine-induced thrombotic thrombocytopaenia; (a) Ad26.COV2.S (Janssen COVID-19 Vaccine); (b) ChAdOx1 nCoV-19 (Vaxevria, Oxford/Astra-Zeneca); (c) Gam-COVID-Vac (Sputnik V, Sputnik Light); and (d) AD5-nCOV (Convidecia);
Note: Examples of adenovirus vector COVID-19 vaccines include:.
- (2)inability to obtain appropriate clinical management for vaccine-induced thrombotic thrombocytopaenia;
Aggravation-only factors: the factors in subsection 8(2) apply only to material contribution to, or aggravation of, the condition where it was suffered or contracted before or during (but did not arise out of) the person’s relevant service.
